Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma (VOR)
NASDAQ:VOR
VOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.63 - $2.43
Previous CloseN/A
Volume424.02K
Average Volume (3M)316.17K
Market Cap
$95.61M
Enterprise Value$17.57M
Total Cash (Recent Filing)$6.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.92
Next Earnings
May 08, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding124,851,550
10 Day Avg. Volume222,102
30 Day Avg. Volume316,172
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.03
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$11.00Price Target Upside1347.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Vor Biopharma News
See All VOR News
---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe company's clinical programs are progressing on track, with a clinical data update expected from Mylotarg-treated patients in the ongoing Phase 1/2 VBP101 study.
Financial PositionVor Biopharma has a sufficient cash position of approximately $91.9M to fund planned operations into the first quarter of 2026.
Regulatory PathwayFDA does not require additional data to start the Phase III trial and agreed with VOR on its design.
Bears Say
Financial PerformanceThe company reported no revenues for FY24 and a net loss per share that was worse than consensus estimates.
Share DilutionLower DCF-derived price target to $6 from $12, following the transaction, due to the growth in outstanding shares.
Stock Price TargetThe 12-month price target for the stock has been lowered from $17.50 to $13.00 due to a risk-adjusted net present value analysis.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VOR FAQ
What was Vor Biopharma’s price range in the past 12 months?
Vor Biopharma lowest stock price was $0.63 and its highest was $2.43 in the past 12 months.
What is Vor Biopharma’s market cap?
Vor Biopharma’s market cap is $95.61M.
When is Vor Biopharma’s upcoming earnings report date?
Vor Biopharma’s upcoming earnings report date is May 08, 2025 which is in 40 days.
How were Vor Biopharma’s earnings last quarter?
Vor Biopharma released its earnings results on Mar 20, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.286 by -$0.154.
Is Vor Biopharma overvalued?
According to Wall Street analysts Vor Biopharma’s price is currently Undervalued.
Does Vor Biopharma pay dividends?
Vor Biopharma does not currently pay dividends.
What is Vor Biopharma’s EPS estimate?
Vor Biopharma’s EPS estimate is -0.25.
How many shares outstanding does Vor Biopharma have?
Vor Biopharma has 124,851,550 shares outstanding.
What happened to Vor Biopharma’s price movement after its last earnings report?
Vor Biopharma reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.286. Following the earnings report the stock price went up 2.353%.
Which hedge fund is a major shareholder of Vor Biopharma?
Currently, no hedge funds are holding shares in VOR
---
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (1347.37% Upside)
$11.00 (1347.37% Upside)
Blogger Sentiment
Bearish
VOR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 16.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.38%
12-Months-Change
Fundamentals
Return on Equity
-94.52%
Trailing 12-Months
Asset Growth
-27.07%
Trailing 12-Months
Company Description
Vor Biopharma
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
---
VOR Stock 12 Month Forecast
Average Price Target
$11.00
▲(1347.37% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering VOR
1 Year
1 Year Success Rate
1/20 ratings generated profit
1 Year Average Return
-48.44%
reiterated a buy rating yesterday
Copying Justin Walsh's trades and holding each position for 1 Year would result in 5.00% of your transactions generating a profit, with an average return of -48.44% per trade.
---